Peptide
Semaglutide
STEP 1 to STEP 5, SELECT, and roughly 15% mean weight loss in obesity without diabetes.
Lægemidlerne
En side pr. lægemiddel. Effektstørrelser, forsøgsdesign og de populationer, de blev målt i.
Dual agonist
Tirzepatide
SURMOUNT-1 and -2, sleep apnoea and heart failure, and about 21% mean weight loss.
Oral
Oral GLP-1
Oral semaglutide and orforglipron — the same mechanism without the injection.
Relateret læsning
Fasting Evidence
Intermittent fasting, time-restricted eating and meal timing, judged on the trial data.
Metabolism Review
Energy expenditure, insulin resistance and metabolic adaptation, without the folklore.
Weight Loss Evidence
Diets, drugs, behaviour and maintenance — ranked by the strength of the evidence behind them.
Sleep Evidence
Sleep, circadian rhythm and the wearables that claim to measure both.
Denne side blev automatisk oversat fra engelsk. Citaterne og tallene er uændrede. Læs den engelske original, hvis noget lyder underligt. Læs den engelske original